Please assess the completion status of the following clinical trial:

Trial Title: Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active axial spondyloarthritis with disease duration ≤5 years, and chronic back pain of ≥3 month duration~* Have either an inadequate response to 30 days of optimal daily doses of at least one non-steroidal anti-inflammatory drug (NSAID) or must be unable to receive a full 30 day maximal NSAID therapy because of intolerance, toxicity or contraindications to NSAIDs~* Females of child-bearing potential must use contraception~* No history of untreated latent or active tuberculosis~Exclusion Criteria:~* Fulfillment of modified New York criteria for ankylosing spondylitis~* Has ever received tumor necrosis factor (TNF)-α targeted therapy or any biological agents~* Any systemic inflammatory condition other than spondyloarthritis~* Serious infection within 2 months~* Any known malignancy or a history of malignancy within the previous 5 years~* Has or had a substance abuse (drug or alcohol) problem within the previous 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Golimumab→Golimumab (Type: EXPERIMENTAL): In Part 1, participants receive golimumab 50 mg, administered subcutaneously (SC) every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 48 weeks treatment with golimumab.)
- Placebo→Golimumab (Type: PLACEBO_COMPARATOR): In Part 1, participants receive placebo, administered SC every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 32 weeks treatment with golimumab.)

Based on this trial design, predict the completion outcome and termination type (if applicable).